((自动化翻译由路透提供，请见免责声明 ))
9月16日 - ** 券商Guggenheim指出，辉瑞公司 的ponsegromab治疗癌症恶病质的中期数据 "引人入胜"；并表示，在预计于明年公布治疗心力衰竭的中期数据之前，投资者的兴趣可能会增加。
** PFE 在欧洲肿瘤内科学会(ESMO) 上公布了该实验药物的数据，结果显示癌症恶病质患者的体重与安慰剂相比有所增加。
** 券商继续看好强生公司 的TAR-200治疗非肌浸润性膀胱癌的数据，该药有望在2025年提交监管申请
** 称默克 的Keytruda的最新数据显示，它将继续重新定义各种肿瘤类型的治疗标准；并称预计百时美施贵宝 的肺癌数据更新影响不大
** 艾伯维 的ESMO "相对平静"，但券商注意到抗体药物共轭物（一类被称为 "制导导弹 "的抗癌药物）的持续开发
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.